Edition:
India

Aurobindo Pharma Ltd (ARBN.NS)

ARBN.NS on National Stock Exchange of India

598.25INR
3:58pm IST
Change (% chg)

Rs7.45 (+1.26%)
Prev Close
Rs590.80
Open
Rs592.30
Day's High
Rs605.80
Day's Low
Rs585.10
Volume
2,321,620
Avg. Vol
3,013,682
52-wk High
Rs838.00
52-wk Low
Rs536.60

Latest Key Developments (Source: Significant Developments)

India's Aurobindo Pharma March-Qtr Consol Net Profit Rises
Tuesday, 28 May 2019 

May 28 (Reuters) - Aurobindo Pharma Ltd ::MARCH QUARTER CONSOL NET PROFIT 5.85 BILLION RUPEES VERSUS PROFIT OF 5.29 BILLION RUPEES LAST YEAR.MARCH QUARTER CONSOL INCOME FROM OPERATIONS 52.02 BILLION RUPEES VERSUS 39.89 BILLION RUPEES LAST YEAR.MARCH QUARTER EXCEPTIONAL ITEM 361.8 MILLION RUPEES.AUROBINDO PHARMA-APPROVED SCHEME OF AMALGAMATION OF ITS UNITS WITH CO.  Full Article

India's Aurobindo Pharma To File With Federal Court Denying Each Of Relevant Accusations
Tuesday, 14 May 2019 

May 14 (Reuters) - Aurobindo Pharma Ltd ::VARIOUS U.S. STATES FILED 2ND LAWSUIT ALLEGING AUROBINDO, OTHERS VIOLATED ANTITRUST LAWS BY FIXING PRICES AND ALLOCATING CUSTOMERS.CO TO FILE PAPERS WITH FEDERAL COURT IN DUE COURSE DENYING EACH OF RELEVANT ACCUSATIONS.DOES NOT, AT THIS TIME, ANTICIPATE THAT THESE MATTERS WILL HAVE A MATERIAL IMPACT ON CO'S OPERATIONS OR BUSINESS RESULTS.  Full Article

Health Canada Says Auro Pharma Voluntarily Recalls One Lot Of Auro-Irbesartan HCT Tablets Because Of Nitrosamine Impurity
Friday, 19 Apr 2019 

April 18 (Reuters) - Aurobindo Pharma Ltd ::HEALTH CANADA - AURO PHARMA INC VOLUNTARILY RECALLS ONE LOT OF AURO-IRBESARTAN HCT TABLETS BECAUSE OF NITROSAMINE IMPURITY.  Full Article

Aurobindo Pharma's U.S. Unit Recalled Some Amlodipine Valsartan Tablets, Valsartan Hctz Tablets, Valsartan Tablets On Dec 31
Monday, 28 Jan 2019 

Jan 28 (Reuters) - Aurobindo Pharma Ltd ::US UNIT INITIATED VOLUNTARY RECALL OF 80 LOTS OF AMLODIPINE VALSARTAN TABLETS , VALSARTAN HCTZ TABLETS, VALSARTAN TABLETS ON DEC 31.SAYS VALUE OF PRODUCTS BEING RECALLED IS NOT MATERIAL .  Full Article

Aurobindo Pharma Gets U.S. FDA Approval For Vecuronium Bromide Injection
Monday, 24 Dec 2018 

Dec 24 (Reuters) - Aurobindo Pharma Ltd ::GETS USFDA APPROVAL FOR VECURONIUM BROMIDE INJECTION.PRODUCT WILL BE LAUNCHED IN Q4FY19.  Full Article

India's Aurobindo Pharma Gets U.S FDA Approval For Potassium Chloride ER Tablets
Friday, 21 Dec 2018 

Dec 21 (Reuters) - Aurobindo Pharma Ltd ::GETS U.S FDA APPROVAL FOR POTASSIUM CHLORIDE ER TABLETS.SAYS POTASSIUM CHLORIDE TABLETS ARE INDICATED FOR THE TREATMENT OF HYPOKALEMIA.PRODUCT WILL BE LAUNCHED IN JANUARY 2019.  Full Article

Aurobindo Pharma Says Co Not Yet Served With Legal Notice W.R.T. U.S. Suit Over Impurities
Thursday, 6 Dec 2018 

Dec 6 (Reuters) - Aurobindo Pharma Ltd ::AUROBINDO PHARMA CLARIFIES ON NEWS REPORT ON CO FACING U.S. SUIT OVER IMPURITIES.HAVE NOT YET BEEN SERVED WITH LEGAL NOTICE.  Full Article

European Medicines Agency Says EU Authorities Placing Zheijiang Huahai Under Increased Supervision
Monday, 15 Oct 2018 

Oct 15 (Reuters) - European Medicines Agency::EUROPEAN MEDICINES AGENCY - EU AUTHORITIES ARE PLACING THE CHINESE COMPANY ZHEIJIANG HUAHAI UNDER INCREASED SUPERVISION.EMA SAYS INSPECTION FINDINGS INCLUDED DEFICIENCIES IN THE WAY ZHEIJIANG HUAHAI INVESTIGATED IMPURITIES IN ITS VALSARTAN PRODUCTS.EUROPEAN MEDICINES AGENCY SAYS AUROBINDO PHARMA STOPPED FROM SUPPLYING IRBESARTAN TO THE EU.EMA SAYS AUTHORITIES IN EU CURRENTLY CONSIDERING WHETHER TO RECALL MEDICINES CONTAINING AUROBINDO PHARMA’S IRBESARTAN FROM PHARMACIES AS A PRECAUTION.EMA SAYS MARKETING AUTHORISATION HOLDERS FOR EU MEDICINES TO BE REQUIRED TO PERFORM MORE TESTS ON ALL ACTIVE SUBSTANCES SUPPLIED BY ZHEJIANG HUAHAI.EMA- PLACING ZHEIJIANG HUAHAI UNDER INCREASED SUPERVISION AFTER INSPECTIONS SHOWED WEAKNESSES IN QUALITY MANAGEMENT AT ITS CHUANNAN SITE IN LINHAI.  Full Article

Aurobindo Pharma Gets Approval From South African Regulator For Certain Tablets
Tuesday, 18 Sep 2018 

Sept 18 (Reuters) - Aurobindo Pharma Ltd ::AUROBINDO PHARMA -APPROVAL FROM SOUTH AFRICAN HEALTH PRODUCTS REGULATORY AUTHORITY FOR DOLUTEGRAVIR, LAMIVUDINE, TENOFOVIR DISOPROXIL FUMARATE TABLETS.  Full Article

Novartis AG Says Faces Impairment Of About Usd70 Million Related To Sale Of Assets To India's Aurobindo, Will Confirm At Q3 Earnings Report On Oct 18
Thursday, 6 Sep 2018 

Novartis Ag ::SAYS FACES IMPAIRMENT OF ABOUT USD70 MILLION RELATED TO SALE OF ASSETS TO INDIA'S AUROBINDO, WILL CONFIRM AT Q3 EARNINGS REPORT ON OCT 18.SAYS FACES IMPAIRMENT OF ABOUT USD70 MILLION RELATED TO SALE OF ASSETS TO INDIA'S AUROBINDO, WILL CONFIRM AT Q3 EARNINGS REPORT ON OCT 18.  Full Article

BUZZ-India's Aurobindo Pharma at over 4-1/2-month high; chart points to more upside

** Shares of Aurobindo Pharma Ltd gain as much as 3.68 pct to 824.8 rupees, highest since Dec 5, 2018